The most common and most costly revenue leak in laboratory billing is the diagnosis-procedure mismatch. Every test billed must be supported by an ICD-10 diagnosis code that the applicable LCD or NCD recognizes as a covered indication for that test. A claim for a vitamin D level submitted without a diagnosis that supports deficiency risk gets denied. A hemoglobin A1c claim submitted outside the covered frequency window for the attached diagnosis gets denied. Submitting genetic testing without the specific hereditary risk indicator or confirmed diagnosis required by the payer gets denied. These are not random errors. They follow predictable, recurring patterns that a well-designed billing system should prevent before submission every time, not occasionally.

The gap between when a laboratory adds a new test to its menu and when its billing team has the correct, payer-approved code for that test is one of the most expensive silent revenue drains in the industry. In the absence of the correct CPT or PLA code, billing teams often default to CPT 81479 (unlisted molecular pathology procedure). Since January 2026, most commercial payers have hardcoded that code against any test for which a specific code exists — meaning those claims are being auto-denied before a human reviewer ever sees them.

The correct path for proprietary assays is to identify the specific PLA U-code that corresponds to your test, confirm it has been accepted by the relevant MAC, and submit with full medical necessity documentation. That process requires an ongoing test menu mapping review that most in-house billing teams do not have the capacity to maintain.

High-value molecular diagnostic panels, genetic testing for hereditary conditions, pharmacogenomics testing, and liquid biopsy assays all require prior authorization from most major commercial payers — and increasingly from Medicare Advantage plans as well. One missed authorization on a $3,000 NGS panel is a significant claim loss. When that pattern repeats across dozens of patients per month because no one is tracking authorization requirements proactively, the revenue impact compounds quickly.

Toxicology laboratories face a uniquely complex billing environment driven by the distinction between presumptive drug testing (G0477–G0479) and definitive drug testing (G0480–G0483). Presumptive tests screen for the presence or absence of a drug class. Definitive tests identify and quantify specific substances using methods like mass spectrometry. Each tier has specific documentation requirements, frequency limits, and medical necessity thresholds. Billing a definitive test without documentation that a presumptive screen was performed and was positive or without medical justification for proceeding directly to definitive testing is one of the most common and most scrutinized denial triggers in the toxicology billing space.

Laboratory billing relies heavily on correct modifier application. Modifier 90 is required when a reference laboratory performs a test ordered by a different facility. Modifier 91 is required for repeat laboratory testing on the same day. Modifier QW is required for CLIA-waived tests billed under Medicare. Modifier 59 is required to document distinct procedural services that would otherwise appear to be duplicate billing. And for pathology, modifiers 26 (professional component) and TC (technical component) are critical to correctly separating physician interpretation from the technical laboratory work.

Pathology billing carries more revenue per claim than most laboratory billing environments, and the margin for coding accuracy is correspondingly narrow. The difference between CPT 88305 (moderate complexity surgical pathology) and 88307 (higher complexity) is not just a coding distinction it can represent a significant difference in reimbursement per specimen. When pathology specimens are systematically undercoded because the billing team defaults to the lower-complexity code for efficiency, the revenue impact across high-volume pathology services accumulates quickly.

Immunohistochemistry, frozen section billing, flow cytometry, and intraoperative consultation coding all have specific requirements that must be correctly applied. Each component billed incorrectly or not billed at all is revenue your laboratory earned and will never collect.